Compliance barriers in glaucoma: A systematic classification

Journal of Glaucoma

Volumn 12, Issue 5, 2003, Pages 393-398

  Tsai, James C ^a,b   McClure, Cori A ^b   Ramos, Sarah E ^b   Schlundt, David G ^b   Pichert, James W ^b  

^a New York Presbyterian Hospital   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Compliance; Glaucoma; Medication; Taxonomy

Indexed keywords

ANTIGLAUCOMA AGENT;

ADULT; AGED; ARTICLE; CLASSIFICATION; CLINICAL ARTICLE; CLUSTER ANALYSIS; DRUG DOSE REGIMEN; ENVIRONMENTAL FACTOR; FEMALE; FREQUENCY ANALYZER; GLAUCOMA; HEALTH CARE PERSONNEL; HUMAN; MALE; MEDICAL RECORD; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; PROBLEM SOLVING; PROCESS OPTIMIZATION; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CLUSTER ANALYSIS; FEMALE; GLAUCOMA; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES;

EID: 0141928070     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/00061198-200310000-00001     Document Type: Article

References (17)

1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80:389-393.
2. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci. 1997;38:83-91.
3. Kendrick R. Gradual painless visual loss: glaucoma. Clin Geriatr Med. 1999;15:95-101.
4. Kahn HA, Milton RC. Revised Framingham Eye Study prevalence of glaucoma and diabetic retinopathy. Am J Epidemiol. 1980;111:769-776.
5. Schlundt DG, Pichert JW, Rea MR, et al. Situational obstacles to adherence for adolescents with diabetes. Diabetes Educ. 1994;20:207-211.
6. Schlundt DG, Rea MR, Kline SS, et al. Situational obstacles to dietary adherence for adults with diabetes. J Am Diet Assoc. 1994;94:874-879.
7. Schlundt DG, McFall RM. Classifying social situations: a comparison of five methods. Behav Assess. 1987;9:21-42.
8. Hugues FC, Le Jeunne C. System and local tolerability of ophthalmic drug formulations. An update. Drug Saf. 1993;8:365-380.
9. Kass MA, Meltzer DW, Gordon M, et al. Compliance with topical pilocarpine treatment. Am J Ophthalmol. 1986;101:515-523.
10. Kass MA, Gordon M, Morley RE, et al. Compliance with topical timolol treatment. Am J Ophthalmol. 1987;103:188-193.
11. Camras CB. The United States Latanoprost Study Group: comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology. 1996;103:138-147.
12. Schuman JS, Horwitz B, Choplin NT, et al. and the Chronic Brimonidine Study Group. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. Arch Ophthalmol. 1997;115:847-852.
13. Strahlman E, Tipping R, Vogel R, and the International Dorzolamide Study Group. A double-masked, randomized, 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch Ophthalmol. 1995;113:1009-1016.
14. Gurwitz JH, Glynn RJ, Monane M, et al. Treatment for glaucoma: adherence for the elderly. Am J Public Health. 1993;83:711-716.
15. Rotchford AP, Murphy KM. Compliance with timolol treatment in glaucoma. Eye. 1998;12:234-236.
16. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995;26:233-236.
17. Taylor SA, Galbraith SM, Mills RP. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J Ocul Pharmacol Ther. 2002;18:401-409.